In CKD-MBD, which statement best describes vascular calcification risk?

In CKD-MBD, which statement best describes vascular calcification risk?

• A. CKD-MBD increases vascular calcification risk
• B. CKD-MBD reduces vascular calcification risk
• C. Vascular calcifications are unrelated to CKD-MBD
• D. Only hypercalcemia drives vascular calcification in CKD

Answer: (A)

In CKD-MBD, mineral metabolism is disrupted, and that disruption promotes calcification in the vessel walls. When the kidneys fail to clear phosphate, serum phosphate tends to rise. The combination of elevated phosphate with even modest changes in calcium increases the calcium–phosphate product, which drives calcium phosphate deposition in the vascular wall. Vascular smooth muscle cells respond to this hostile mineral environment by taking on bone-like properties and forming matrix that calcifies over time. Add to this the loss of natural inhibitors of calcification in CKD—proteins like fetuin-A and matrix Gla protein, along with reduced klotho activity—and the tendency toward vascular calcification becomes even stronger. This whole process explains why CKD-MBD raises the risk of vascular calcification and is linked to worse cardiovascular outcomes. The other statements don’t fit because vascular calcification in CKD-MBD is not reduced, and it is not unrelated to CKD-MBD. It isn’t driven solely by high calcium; high phosphate and impaired calcification inhibitors play major roles, and even with normal calcium levels, calcification can progress due to phosphate burden and dysregulated mineral metabolism.

In CKD-MBD, mineral metabolism is disrupted, and that disruption promotes calcification in the vessel walls. When the kidneys fail to clear phosphate, serum phosphate tends to rise. The combination of elevated phosphate with even modest changes in calcium increases the calcium–phosphate product, which drives calcium phosphate deposition in the vascular wall. Vascular smooth muscle cells respond to this hostile mineral environment by taking on bone-like properties and forming matrix that calcifies over time. Add to this the loss of natural inhibitors of calcification in CKD—proteins like fetuin-A and matrix Gla protein, along with reduced klotho activity—and the tendency toward vascular calcification becomes even stronger. This whole process explains why CKD-MBD raises the risk of vascular calcification and is linked to worse cardiovascular outcomes.

The other statements don’t fit because vascular calcification in CKD-MBD is not reduced, and it is not unrelated to CKD-MBD. It isn’t driven solely by high calcium; high phosphate and impaired calcification inhibitors play major roles, and even with normal calcium levels, calcification can progress due to phosphate burden and dysregulated mineral metabolism.